You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 727 Increased serum levels of EBI3 are associated with poor outcome in hepatocellular carcinoma patients and SRF388, a first-in-class IL-27 blocking antibody, inhibits the growth of murine liver tumors

Article Text

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Novel single-agent immunotherapies
727 Increased serum levels of EBI3 are associated with poor outcome in hepatocellular carcinoma patients and SRF388, a first-in-class IL-27 blocking antibody, inhibits the growth of murine liver tumors

https://doi.org/10.1136/jitc-2020-SITC2020.0727

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.